Inventor · disambiguated record
Anthony A. Estrada
Also filed as: ESTRADA ANTHONY · ESTRADA ANTHONY A
42 granted patents·28 pending applications·282 citations·filing 2011–2025
97Inventor score
Files withDENALI THERAPEUTICS INC45GENENTECH INC17NICO THERAPEUTICS INC3BAKER-GLENN CHARLES1CHAN BRAYN1
Top patents by PatentIndex Score
70 records- 0197US11111235B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·7 cites·26 claims
- 0297US9896458B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Feb 20, 2018·23 cites·6 claims
- 0397US9815850B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·36 cites·41 claims
- 0496US9932325B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Apr 3, 2018·16 cites·30 claims
- 0594US9212173B2Pyrazole aminopyrimidine derivatives as LRRK2 modulatorsGENENTECH INC·Filed 2014·Granted Dec 15, 2015·18 cites·3 claims
- 0693US8815882B2Pyrazole aminopyrimidine derivatives as LRRK2 modulatorsBAKER-GLENN CHARLES·Filed 2011·Granted Aug 26, 2014·34 cites·22 claims
- 0793US8354420B2Aminopyrimidine derivatives as LRRK2 inhibitorsGENENTECH INC·Filed 2011·Granted Jan 15, 2013·27 cites·26 claims
- 0892US9212186B2Bicyclic pyrazole LRRK2 small molecule inhibitorsGENENTECH INC·Filed 2014·Granted Dec 15, 2015·11 cites·18 claims
- 0991US11306077B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Apr 19, 2022·2 cites·47 claims
- 1090US11591316B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Feb 28, 2023·1 cites·20 claims
- 1190US10590114B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 17, 2020·5 cites·27 claims
- 1290US8791130B2Aminopyrimidine derivatives as LRRK2 modulatorsGENENTECH INC·Filed 2012·Granted Jul 29, 2014·18 cites·21 claims
- 1389US9145402B2Aminopyrimidine derivatives as LRRK2 modulatorsGENENTECH INC·Filed 2012·Granted Sep 29, 2015·15 cites·20 claims
- 1489US2025034119A1Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1588US9139566B2Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2GENENTECH INC·Filed 2012·Granted Sep 22, 2015·6 cites·12 claims
- 1688US8802674B2Aminopyrimidine derivatives as LRRK2 modulatorsGENENTECH INC·Filed 2012·Granted Aug 12, 2014·12 cites·15 claims
- 1788US8796296B2Aminopyrimidine derivatives as LRRK2 modulatorsGENENTECH INC·Filed 2012·Granted Aug 5, 2014·14 cites·21 claims
- 1886US10604535B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Mar 31, 2020·3 cites·18 claims
- 1986US10131676B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2017·Granted Nov 20, 2018·3 cites·33 claims
- 2086US8809331B2Aminopyrimidine derivatives as LRRK2 modulatorsGENENTECH INC·Filed 2012·Granted Aug 19, 2014·12 cites·5 claims
- 2185US12358928B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2023·Granted Jul 15, 2025·0 cites·8 claims
- 2285US11834439B2Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2023·Granted Dec 5, 2023·0 cites·19 claims
- 2384US10179782B2Substituted sulfonamide compoundsGENENTECH INC·Filed 2016·Granted Jan 15, 2019·5 cites·10 claims
- 2484US2025388601A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2583US11203600B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 21, 2021·2 cites·24 claims
- 2680US11236100B2Modulators of eukaryotic initiation factor 2B, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·1 cites·30 claims
- 2780US2025011338A1Kinase Inhibitors and Uses ThereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2879US2024140919A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2978US8569281B2Compounds and their administration for treating a neurodegenerative disease as well as a method for identifying a compound capable of inhibiting a kinase, such as LRRKCHAN BRYAN K·Filed 2011·Granted Oct 29, 2013·9 cites·9 claims
- 3076US11028080B2Substituted pyrimidines as LRKK2 inhibitorsDENALI THERAPEUTICS INC·Filed 2017·Granted Jun 8, 2021·1 cites·53 claims
- 3176US2023250072A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3275US11851440B2Modulators of eukaryotic initiation factor 2B, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·0 cites·18 claims
- 3373US12139478B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2024·1 cites·57 claims
- 3473US2023043400A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3572US11236046B2Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulatorsGENENTECH INC·Filed 2019·Granted Feb 1, 2022·0 cites·1 claims
- 3669US12180211B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 31, 2024·0 cites·5 claims
- 3769US12129263B2Kinase inhibitors and uses thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Oct 29, 2024·0 cites·19 claims
- 3869US2020317691A1Compounds, Compositions and MethodsDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3968US11958840B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2022·Granted Apr 16, 2024·0 cites·45 claims
- 4068US2022153728A1Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4167US11851433B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 26, 2023·0 cites·17 claims
- 4267US11840529B2Substituted pyrimidines as LRKK2 inhibitorsDENALI THERAPEUTICS INC·Filed 2021·Granted Dec 12, 2023·0 cites·38 claims
- 4367US2022119371A1Compound, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4465US11072618B2Compounds, compositions and methodsDENALI THERAPEUTICS INC·Filed 2019·Granted Jul 27, 2021·0 cites·17 claims
- 4565US2025388595A1Modulators of eukaryotic initiation factor 2b, compositions and methodsDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4664US2021130308A1Modulators of eukaryotic initiation factor 2DENALI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4764US2017362206A1Compounds, compositions, and methodsDENALI THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4861US2024299575A1Oligonucleotide conjugates targeted to the transferrin receptorDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4961US2025361234A1Compounds, compositions, and methodsNICO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 5059US2025171462A1Compounds, compositions, and methodsNICO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 70 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →